Replimune gives cancer immunotherapy a third try after FDA leadership shakeup
BioSpace
Replimune's resubmission for RP1 for melanoma comes amid the departures of FDA leaders in place at the time of the drug's first two rejections, last summer and again in April.
pharminent
May 29, 2026 (Last updated: May 30, 2026)
BioSpace
Replimune’s resubmission for RP1 for melanoma comes amid the departures of FDA leaders in place at the time of the drug’s first two rejections, last summer and again in April.
